CRISPR Therapeutics’ (CRSP) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a report published on Tuesday morning,Benzinga reports. Chardan Capital currently has a $94.00 price target on the stock.

Several other equities research analysts have also recently weighed in on the stock. Truist Financial cut their price objective on shares of CRISPR Therapeutics from $120.00 to $100.00 and set a “buy” rating for the company in a research report on Monday, August 12th. Royal Bank of Canada reaffirmed a “sector perform” rating and set a $53.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a “sell” rating in a research report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a research report on Wednesday, November 6th. Finally, Barclays cut their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating for the company in a research report on Wednesday, November 6th. Two research analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $77.93.

CRISPR Therapeutics Trading Down 5.0 %

NASDAQ:CRSP opened at $45.40 on Tuesday. CRISPR Therapeutics has a 1-year low of $43.42 and a 1-year high of $91.10. The firm has a fifty day simple moving average of $48.83 and a 200 day simple moving average of $51.29. The stock has a market capitalization of $3.88 billion, a PE ratio of -16.04 and a beta of 1.62.

CRISPR Therapeutics (NASDAQ:CRSP) last released its earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million during the quarter, compared to analysts’ expectations of $6.65 million. During the same period last year, the business earned ($1.41) earnings per share. On average, equities analysts predict that CRISPR Therapeutics will post -5.17 earnings per share for the current fiscal year.

Insider Activity

In other CRISPR Therapeutics news, General Counsel James R. Kasinger sold 1,089 shares of the business’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now owns 62,597 shares in the company, valued at approximately $2,896,989.16. The trade was a 1.71 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Samarth Kulkarni sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total value of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares of the company’s stock, valued at $10,931,554.80. The trade was a 13.24 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 50,382 shares of company stock worth $2,744,179. 4.10% of the stock is currently owned by insiders.

Hedge Funds Weigh In On CRISPR Therapeutics

Several hedge funds have recently made changes to their positions in the business. Franklin Resources Inc. increased its stake in shares of CRISPR Therapeutics by 12.7% during the third quarter. Franklin Resources Inc. now owns 7,097 shares of the company’s stock valued at $339,000 after buying an additional 800 shares during the period. Wilmington Savings Fund Society FSB purchased a new stake in CRISPR Therapeutics in the third quarter worth $40,000. Sanctuary Advisors LLC grew its stake in CRISPR Therapeutics by 17.8% in the third quarter. Sanctuary Advisors LLC now owns 8,317 shares of the company’s stock worth $398,000 after purchasing an additional 1,258 shares during the period. Sunbelt Securities Inc. grew its stake in CRISPR Therapeutics by 11.3% in the third quarter. Sunbelt Securities Inc. now owns 2,955 shares of the company’s stock worth $139,000 after purchasing an additional 300 shares during the period. Finally, Geode Capital Management LLC grew its stake in CRISPR Therapeutics by 3.6% in the third quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after purchasing an additional 35,196 shares during the period. 69.20% of the stock is owned by hedge funds and other institutional investors.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.